The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
ApexOnco Front Page
Recent articles
But Tevimbra’s role looks shaky as adverse events loom.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
Key FDA decisions are expected to face delays.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
